NEW YORK (GenomeWeb) – Molecular diagnostics firm Transgenomic today reported a sharp drop of 69 percent in first quarter sales reflecting the phasing of contracts due to client sample availability issues, but said that this effect is expected to be "transitory."

For the three-month period ended March 31, Transgenomics' net sales fell to $236,000 from $750,000 the year before. However, the company said it expects the effect causing the drop to be transitory.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.